Iterum Therapeutics plc announced the expansion of market access for its antibiotic product, ORLYNVAH™, through a new commercial contract with a Group Purchasing Organization working with one of the largest Pharmacy Benefit Managers (PBMs) in the United States. This agreement is expected to provide coverage opportunities for more than 24 million lives starting in early 2026. In addition, Iterum Therapeutics has signed another rebate agreement with one of the top three Medicare Part D PBMs, positioning ORLYNVAH™ for inclusion on Medicare Advantage Prescription Drug and Medicare Prescription Drug formularies, with coverage for over 10 million lives anticipated to begin as early as the first quarter of 2026. The company expects to finalize additional agreements with other major PBMs in the near future.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iterum Therapeutics plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9616336-en) on December 23, 2025, and is solely responsible for the information contained therein.